Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research Annual Meeting 2026
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Sankamap Expands Exploration Footprint at Fauro as Systematic Prospecting Advances and New Gold Targets Emerge
NevGold Defines Multiple High-Priority Drill Targets Including Key Feeder Structures at Nutmeg Mountain Gold Project, Idaho
Brixton Drills 58 m of 0.50 g/t AuEq and 17.6 m of 1.47 g/t AuEq in the Glenfiddich Zone at Camp Creek, Thorn Project
SAGA Metals Advances Radar Project to Stage 2 RCL Optimization Targeting First High-Purity Titanium, Vanadium and Iron Products